Full Press Release Details
terna Zentaris Inc. 1405 du Parc-Technologique Blvd.
Qu bec (Qu bec) Canada G1P 4P5 T 418 652-8525 F 418 652-0881
| Press Release | ||
| For immediate release |
Aeterna Zentaris Announces At-the-Market Issuance Program
City, Canada, June 29, 2011 Aeterna Zentaris Inc. (NASDAQ: AEZS;
TSX: AEZ) (the Company ), a late-stage drug development company specialized in oncology and
endocrine therapy, announced today that it has entered into an At-the-Market ( ATM ) Sales
Agreement, dated June 29, 2011, with McNicoll, Lewis Vlak LLC ( MLV ), under which the
Company may, at its discretion, from time to time during the 24-month term of the agreement, sell
up to a maximum of 9,500,000 of its common shares through ATM issuances on the NASDAQ Stock Market.
MLV will act as sales agent for any sales made under the ATM. The common shares will be sold at
market prices prevailing at the time of the sale of common shares, and, as a result, prices may
In connection with the signature of the ATM Sales Agreement with MLV, the Company has filed a
prospectus supplement dated June 29, 2011 to its U.S. shelf prospectus, dated July 15, 2010,
forming part of its U.S. registration statement on Form F-10 with the United States Securities and
Exchange Commission ( SEC ) as well as a prospectus supplement to its Canadian final base shelf
prospectus dated July 15, 2010.
The U.S. shelf prospectus and the supplement thereto have been filed with the SEC on the SEC s
website (www.sec.gov) and the Canadian final base shelf prospectus and the supplement thereto have
been filed on the SEDAR website maintained by the Canadian Securities Administrators at
www.sedar.com. Alternatively, MLV will provide copies of the U.S. documents upon request by
contacting McNicoll, Lewis Vlak LLC, Attention: Randy Billhardt, 1251 Avenue of the Americas,
41st Floor, New York, NY 10020, or by calling 212-580-5881,
while copies of the Canadian documents may be obtained by contacting the Company s Investor
Relations department directly by calling (418) 652-8525, ext. 265.
This press release does not and shall not constitute an offer to sell or the solicitation of an
offer to buy any of the common shares, nor shall there be any sale of the common shares in any
state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such state or jurisdiction.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development company currently investigating
potential treatments for various cancers including colorectal, ovarian, endometrial cancer and
multiple myeloma. The Company s innovative approach of personalized medicine means tailoring
treatments to a patient s specific condition and to unmet medical needs. Aeterna Zentaris deep
pipeline is drawn from its proprietary discovery unit providing the Company with constant and
long-term access to state-of-the-art therapeutic options. For more information please visit
Investor Relations Coordinator
(418) 652-8525 ext. 265
Director of Communications
(418) 652-8525 ext. 406